A Review of the Structural and Functional Features of Olmesartan Medoxomil, An Angiotensin Receptor Blocker

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Cardiovascular Pharmacology

• Publication date

  2005-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1097/01.fjc.0000180902.78230.fdPMID 16220064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How can the differences among AT1-receptor antagonists Be explained?

  2007cited by this paper
• Use of 24-Hour Ambulatory Blood Pressure Monitoring to Assess Antihypertensive Efficacy

  2005cited by this paper
• Recognition of privileged structures by G-protein coupled receptors.

  2004cited by this paper
• From viper's venom to drug design: treating hypertension

  2004cited by this paper
• The dose-dependent antihypertensive actions of olmesartan medoxomil, an angiotensin II (AT-II) receptor blocker

  2004influential reference
• Review: Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?

  2003cited by this paper
• How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: According to blood pressure or proteinuria?

  2003cited by this paper
• Therapeutic role of angiotensin II receptor blockers in the treatment of heart failure.

  2003cited by this paper
• The role of renin–angiotensin– aldosterone system inhibition in chronic kidney disease

  2003cited by this paper
• Olmesartan medoxomil, a novel potent angiotensin II blocker

  2003influential reference
• Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study.

  2002cited by this paper
• The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview

  2002cited by this paper
• 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods.

  2002cited by this paper
• Models and methods for studying insurmountable antagonism.

  2002cited by this paper
• Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1‐receptor antagonist

  2001cited by this paper
• In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist

  2001cited by this paper
• The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction

  2001cited by this paper
• Comparative Efficacy of Olmesartan, Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension

  2001cited by this paper
• A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.

  2001cited by this paper
• Lys 199 mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists

  2000influential reference
• Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function.

  2000influential reference
• The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II.

  2000influential reference
• Pharmacological properties of angiotensin II receptor antagonists.

  1999cited by this paper
• Angiotensin receptor blockers: pharmacology and clinical significance.

  1999cited by this paper
• Historical evolution of angiotensin II receptor blockers: therapeutic advantages.

  1999cited by this paper
• Pharmacological properties of angiotensin II receptor antagonists.

  1999cited by this paper
• The history of inhibitors of angiotensin converting enzyme.

  1999cited by this paper
• The octapeptide angiotensin II adopts a well-defined structure in a phospholipid environment.

  1998cited by this paper
• Discovery of new angiotensin II receptor antagonists. A review of pharmacological studies.

  1998cited by this paper
• Unraveling the Mystery of Goldblatt Hypertension.

  1998cited by this paper
• Discovery and pharmacological evaluation of new platelet glycoprotein gpIIb/IIIa antagonists.

  1998cited by this paper
• Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds.

  1996influential reference
• A New Class of Antihypertensive Therapy: Angiotensin II Receptor Antagonists

  1996cited by this paper
• Mutagenesis and the Molecular Modeling of the Rat Angiotensin II Receptor (AT1) (*)

  1995cited by this paper
• Tetrazole and Carboxylate Groups of Angiotensin Receptor Antagonists Bind to the Same Subsite by Different Mechanisms (*)

  1995cited by this paper
• Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist.

  1995influential reference
• Receptor interactions of the position 4 side chains of angiotensin II analogues: Importance of aromatic ring quadrupole

  1994cited by this paper
• Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.

  1994cited by this paper
• Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype

  1993cited by this paper
• Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist.

  1993cited by this paper
• Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.

  1993cited by this paper
• New nonpeptide angiotensin II receptor antagonists. 1. Synthesis, biological properties, and structure-activity relationships of 2-alkyl benzimidazole derivatives.

  1992cited by this paper
• Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy

  1992cited by this paper
• New nonpeptide angiotensin II receptor antagonists. 2. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)quinoline derivatives.

  1992cited by this paper
• Angiotensin II Receptor Antagonists From Discovery to Antihypertensive Drugs

  1991cited by this paper
• The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives.

  1990cited by this paper
• Structure-activity relationships for the carboxy-terminus truncated analogues of angiotension II, a new class of angiotensin II antagonists.

  1990cited by this paper
• Sarmesin is a partial agonist of angiotensin-II receptors in rabbit, but not in rat, aortic rings.

  1990cited by this paper
• Sarmesin is a partial agonst of angiotensin-II receptors in rabbit, but not in rat, aortic rings

  1990cited by this paper
• 1H-NMR studies of sarmesin and [des1]sarmesin conformation in dimethylsulfoxide by nuclear Overhauser effect (NOE) enhancement spectroscopy: folding of the N- and C-terminal domains.

  1990cited by this paper
• I. 1H-NMR studies of [Sar1]angiotensin II conformation by nuclear Overhauser effect spectroscopy in the rotating frame (ROESY): Clustering of the aromatic rings in dimethylsulfoxide

  1990influential reference
• Mechanistic consequences of charge transfer systems in serine proteases and angiotensin: semiempirical computations.

  1987cited by this paper
• Adverse Reactions with Angiotensin Converting Enzyme (ACE) Inhibitors

  1986cited by this paper
• Angiotensin as a model for hormone — receptor interactions

  1985cited by this paper
• Angiotensin-dependent renal mechanisms in two-kidney, one-clip renal vascular hypertension.

  1983cited by this paper
• Development and design of specific inhibitors of angiotensin-converting enzyme.

  1982cited by this paper
• STUDIES ON EXPERIMENTAL HYPERTENSION

  1934cited by this paper

• Advanced lipid-based niosomes for enhanced transdermal delivery of olmesartan medoxomil via intracutaneous drug depot: a novel biomimicry approach.

  2025cites this paper
• Development of Novel Olmesartan Medoxomil Loaded Leciplex for Enhanced Oral Bioavailability: Formulation, Histopathological Analysis, and In Vivo Pharmacokinetic Studies

  2025cites this paper
• Comparison of Adverse Events Among Angiotensin Receptor Blockers in Hypertension Using the United States Food and Drug Administration Adverse Event Reporting System

  2025cites this paper
• An Investigative Review for PharmaceuticalAnalysis of Angiotensin receptor blockers: Olmesartan Medoxomil.

  2024cites this paper
• Efficacy of combined antihypertensive therapy in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease with various polymorphisms of the CYP2C9 gene

  2024cites this paper
• Drug Delivery with Hyaluronic Acid-Coated Polymeric Micelles in Liver Fibrosis Therapy.

  2023cites this paper
• Preparation and Optimization of Microwave-Assisted Ball-Milled Olmesartan Medoxomil with Chitosan Using Full 32 Factorial Design

  2023influential citation
• Safety and cardiovascular effectiveness of olmesartan in combination therapy for advanced hypertension: an electronic health record-based cohort study

  2023cites this paper
• The efficacy of olmesartan/amlodipine combination in hypertension treatment – a systematic review

  2022cites this paper
• Chemometric Assisted Spectrophotometric Method for the Simultaneous Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Bulk and Tablet Dosage Form

  2022cites this paper
• Olmesartan Ameliorates Organ Injury and Mortality in Rats With Peritonitis-Induced Sepsis.

  2022cites this paper
• Identification, Synthesis, and Comprehension of an Imidazole N-3 Regioisomeric Impurity of Olmesartan Medoxomil Key Intermediate

  2022cites this paper
• Dosing time optimization of antihypertensive medications by including the circadian rhythm in pharmacokinetic-pharmacodynamic models

  2022cites this paper
• Stability of Olmesartan Medoxomil Extemporaneous Suspensions

  2021cites this paper
• Olmesartan modulates proliferating cell nuclear antigen expression and improves dextran sulfate: induced ulcerative colitis in rats

  2021cites this paper
• Solid State Characterization of Olmesartan medoximil Solid Dispersion and in-silico Formulation Design using Quality by Design Techniques Engendered by Definitive Screening Design

  2021cites this paper
• Sartans: What they are for, how they degrade, where they are found and how they transform

  2021cites this paper
• Comparative Efficacy of Angiotensin II Type 1 Receptor Blockers Against Ventilator‐Induced Diaphragm Dysfunction in Rats

  2020cites this paper
• Heteromultivalent Nanoparticles for Selective Targeting of Renal Cells

  2020cites this paper
• Sustained release olmesartan medoxomil loaded PLGA nanoparticles with improved oral bioavailability to treat hypertension

  2020cites this paper
• DEVELOPMENT AND VALIDATION OF REVERSED-PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY TECHNIQUE WITH ULTRAVIOLET DETECTION FOR ESTIMATION OF FAMOTIDINE IN RABBIT PLASMA

  2020influential citation
• Gingival overgrowth caused by Olmesartan Medoxomil: Observational study

  2019cites this paper
• Elemental distribution in the aortic arch using LEXRF: Side effects of angiotensin receptor blockers as antihypertensive treatment

  2019cites this paper
• UV Spectrophotometric Determination of Olmesartan Medoxomil in Pure and Pharmaceutical Formulation

  2019cites this paper
• FORCED DEGRADATION STUDIES OF OLMESARTAN MEDOXOMIL AND CHLORTHALIDONE: DEVELOPMENT AND VALIDATION OF STABILITY-INDICATING RP‑HPLC METHOD

  2019cites this paper
• Estudo de alterações em artérias de ratos espontaneamente hipertensos após o tratamento com bloqueadores dos receptores da angiotensina II usando microscopia de raios X de baixa energia com radiação síncrotron

  2019cites this paper
• Development and validation of chromatographic and spectroscopic methods for estimation of some Antihypertensive agents and their combined dosage forms

  2018cites this paper
• Development of efficient one-pot three-component assembly of trityl olmesartan medoxomil.

  2018cites this paper
• SIMULTANEOUS ESTIMATION OF OLMESARTAN MEDOXOMIL AND INDAPAMIDE BY STANDARD ADDITION UV SPECTROPHOTOMETRIC METHOD IN THEIR COMBINED DOSAGE FORMS

  2017cites this paper
• Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control

  2017cites this paper
• Olmesartan.

  2017cites this paper
• Management of Hypertension Using Olmesartan Alone or in Combination

  2017cites this paper
• Three-way analysis of the UPLC-PDA dataset for the multicomponent quantitation of hydrochlorothiazide and olmesartan medoxomil in tablets by parallel factor analysis and three-way partial least squares.

  2016cites this paper
• Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.

  2016cites this paper
• Angiotensin-II blockage, muscle strength, and exercise capacity in physically independent older adults

  2016cites this paper
• Chapter 22 – Antihypertensive Drugs

  2016cites this paper
• SIMULTANEOUS DETERMINATION OF AMLODIPINE AND OLMESARTAN IN HUMAN PLASMA BY LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY AND ITS APPLICATION IN PHARMACOKINETIC STUDY

  2016cites this paper
• Persistent olmesartan-based blood pressure–lowering effects on morning hypertension in Asians: the HONEST study

  2016cites this paper
• Drug-Induced Enteropathy

  2015cites this paper
• Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?

  2015cites this paper
• In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity.

  2015cites this paper
• DEVELOPMENT AND VALIDATION OF CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS ESTIMATION OF OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE, CILNIDIPINE IN COMBINATION TABLET DOSAGE FORM

  2015cites this paper
• CODEN: IJPNL6 STABILITY INDICATING RP-HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF OLMESARTAN MEDOXOMIL AND ATORVASTATIN CALCIUM

  2015cites this paper
• Development and Validation of RP-HPLC Method for Determination of Eprosartan Mesylate in Rat Plasma: Application to Preclinical Pharmacokinetic Study

  2015cites this paper
• Case Study: Angiotensin Receptor Blockers (ARBs)

  2015cites this paper
• Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects.

  2014cites this paper
• The application of solid-state NMR spectroscopy to study candesartan cilexetil (TCV-116) membrane interactions. Comparative study with the AT1R antagonist drug olmesartan.

  2014cites this paper
• An efficient synthetic method and theoretical calculations of olmesartan methyl ether: study of biological function of AT1 antagonism.

  2014cites this paper
• pOlmesartan medoxomil surface solid dispersion-based orodispersible tablets: formulation and in vitro characterization

  2014cites this paper
• PROTEIN BINDING INTERACTION STUDY OF OLMESARTAN MEDOXOMIL AND ITS METABOLITE OLMESARTAN BY FLUORESCENCE SPECTROSCOPY

  2014cites this paper
• Angiotensin (1-7) Antagonist Diminished the Anti-Tumor Effect of Olmesartan in Tumor Cell Lines Grown In-vitro and In-vivo

  2014cites this paper
• A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists

  2013influential citation
• Validated voltammetric determination of olmesartan medoxomil: Method development and electrochemical behaviors investigation

  2013cites this paper
• Discovery of olmesartan hexetil: a new potential prodrug of olmesartan.

  2013cites this paper
• Pharmacokinetics of rosuvastatin/olmesartan fixed-dose combination: a single-dose, randomized, open-label, 2-period crossover study in healthy Korean subjects.

  2013cites this paper
• Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist.

  2013cites this paper
• Olmesartan Blocks Advanced Glycation End Products-Induced VCAM-1 Gene Expression in Mesangial Cells by Restoring Angiotensin-Converting Enzyme 2 Level

  2013cites this paper
• Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles.

  2013cites this paper
• Application of a Stability-Indicating HPTLC Method for Simultaneous Quantitative Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Pharmaceutical Dosage Forms

  2013influential citation
• Anti-inflammatory and anti-oxidant activities of olmesartan medoxomil ameliorate experimental colitis in rats.

  2013cites this paper
• Olmesartan Medoxomil Is Associated with Decreased Plasma AGEs, Pentosidine, and N-(Epsilon)-Carboxymethyl-Lysine Levels in Hemodialysis Patients

  2012cites this paper
• Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.

  2012influential citation
• Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.

  2012cites this paper
• Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension

  2012cites this paper
• Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.

  2012cites this paper
• Rapid and selective UV Spectrophotometric method for the analysis of Olmesartan medoxomil in bulk and dosage form

  2012cites this paper
• The Role of Olmesartan Medoxomil-Based Combination Therapy in the Management of Hypertension: A Review for Nurse Practitioners

  2012cites this paper
• Olmesartan Medoxomil

  2012cites this paper
• Formulation and Development of Olmesartan Medoxomil Immediate Release Tablets.

  2012cites this paper
• ANGIOTENSIN II RECEPTOR ANTAGONISTS: A CLASS REVIEW

  2012cites this paper
• Thermal, dynamic and structural properties of drug AT1 antagonist olmesartan in lipid bilayers.

  2011cites this paper
• Prodrug strategies for antihypertensives.

  2011cites this paper
• Multiple templates-based homology modeling enhances structure quality of AT1 receptor: validation by molecular dynamics and antagonist docking

  2011cites this paper
• Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.

  2011cites this paper
• Inhibitory effects of olmesartan on catecholamine secretion from the perfused rat adrenal medulla.

  2010influential citation
• Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives.

  2010cites this paper
• DEVELOPMENT OF LLE AND SPE PROCEDURES AND ITS APPLICATIONS FOR DETERMINATION OF OLMESARTAN IN HUMAN PLASMA USING RP-HPLC AND HPTLC

  2010cites this paper
• Critical appraisal of amlodipine and olmesartan medoxomil fixed-dose combination in achieving blood pressure goals

  2010cites this paper
• Olmesartan Medoxomil

  2010cites this paper
• RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions

  2010cites this paper
• Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.

  2010cites this paper
• Novel amides and esters prodrugs of olmesartan: Synthesis, bioconversion, and pharmacokinetic evaluation.

  2010cites this paper
• Hypertension: Focus on Olmesartan Medoxomil

  2009cites this paper
• Peri-operative evaluation by holter in elderly patients submitted to prostatectomy.

  2009cites this paper
• Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats.

  2009cites this paper
• Complementary Mechanisms of Angiotensin Receptor Blockers and Calcium Channel Blockers in Managing Hypertension

  2009cites this paper
• RP-LC and HPTLC Methods for the Determination of Olmesartan Medoxomil and Hydrochlorothiazide in Combined Tablet Dosage Forms

  2009cites this paper
• An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension.

  2009cites this paper
• Olmesartan medoxomil: a review of its use in the management of hypertension.

  2008cites this paper
• Olmesartan for the treatment of arterial hypertension.

  2008influential citation
• Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor

  2007cites this paper
• Determination of olmesartan medoxomil in tablets by UV-Vis spectrophotometry.

  2007cites this paper
• Development of a CZE Method for the Determination of Olmesartan Medoxomil in Tablets

  2007cites this paper
• Development of a Capillary Zone Electrophoresis Method for the Indirect Determination of Olmesartan Medoxomil and Determination of Hydrochlorothiazide in Synthetic Tablets

  2007cites this paper
• Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update

  2007cites this paper
• Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.

  2007cites this paper
• The pharmacology of agents that interfere with renin-angiotensin system activity

  2006cites this paper
• The Renin Report.

  2006cites this paper
• Angiotensin Receptor Blockers: New Considerations in Their Mechanism of Action

  2006cites this paper